Apollomics

Apollomics is a biotechnology company focused on the discovery and development of oncology combination therapies. Operating in both the U.S. and China, the company leverages partnerships with other biotechnology firms to enhance its capabilities. Founded in 2015, Apollomics has built a pipeline of ten drug candidates across 12 programs, with five candidates at the clinical stage. The pipeline is categorized into three groups based on mechanisms of action: tumor inhibitors, anti-cancer enhancers, and immuno-oncology drugs. Tumor inhibitors include small molecule inhibitors targeting uncontrolled growth signaling pathways, with a c-Met inhibitor as the core product. Anti-cancer enhancers are designed to boost the efficacy of other treatments and include antagonists developed as adjuncts to chemotherapy. Immuno-oncology drugs utilize the body's immune system to combat cancer, featuring mono-specific and bi-specific antibodies and a novel cancer vaccine. Apollomics aims to develop synergistic combination therapies to address unmet needs in cancer treatment.

Keywords: oncology, biotechnology, drug candidates, tumor inhibitors, anti-cancer enhancers, immuno-oncology, combination therapies, clinical stage, cancer treatment, partnerships